Spotlight
Topics
DI Executive
Subscribe
- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Can a New Prostate MRI Software Have an Impact?
Emphasizing restriction spectrum imaging (RSI), the recently launched prostate MRI software OnQ Prostate may enhance PI-RADS assessments and workflow efficiency.
In order to enhance the detection of clinically significant prostate cancer (csPCa), Cortechs.ai has launched OnQ Prostate, a post-processing software that may bolster prostate MRI interpretation through a proprietary diffusion-weighted imaging called restriction spectrum imaging (RSI).
Originally developed for brain cancer imaging, RSI reportedly increases the detection of aggressive cancer cells, according to Cortechs.ai. The company noted that research with the FDA-cleared OnQ Prostate software has demonstrated improved in vivo characterization and localization of csPCa on diffusion MRI imaging.
The FDA-cleared OnQ Prostate software has demonstrated improved in vivo characterization and localization of csPCa on diffusion MRI imaging, according to Cortechs.ai, the developer of the software. (Image courtesy of Cortechs.ai .)
In addition to improved accuracy with PI-RADS assessments, Cortechs.ai said the OnQ Prostate software offers a versatility that can enhance workflows with radiologists and referring providers by facilitating patient selection for biopsy procedures, treatment planning and post-treatment assessment.
“This announcement is an important step in increasing the awareness and accessibility of OnQ Prostate beyond its earliest adopters so that more physicians and patients can benefit from this technology,” says Brittany Hunt, the head of prostate business development at Cortechs.ai.
Recent Videos
Related Content
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024Article
In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Article
Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024Article
New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024Article
The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
